Keyphrases
Aflibercept
24%
Age-related Macular Degeneration
24%
Assessment Training
8%
Best-corrected Visual Acuity
49%
Biosimilar
24%
Bivariate Contour Ellipse Area
16%
Brolucizumab
24%
Consecutive Patients
8%
Contact Lens Sensor
49%
Cut-off Level
10%
Decimals
8%
Endovascular Surgery
49%
Five Eyes
12%
Fixation Stability
16%
Fluorescein Angiography
12%
Glaucoma Patients
49%
Injection Interval
10%
Integrity Assessment
41%
Internal Limiting Membrane
49%
Intraocular Pressure
49%
Intraocular Pressure Fluctuation
43%
Lesion Size
21%
Macular
41%
Macular Edema
12%
Macular Hole
57%
Macular Surgery
49%
Microperimetric Biofeedback Training
49%
Microperimetry
8%
Nasal
8%
Neurofeedback
24%
Non-ischemic
18%
Normal Tension Glaucoma
49%
Polypoidal Choroidal Vasculopathy
24%
Polyps
10%
Preferred Retinal Locus
8%
Reading Speed
16%
Retinal Endovascular Surgery
30%
Retinal pigment Epithelium Tear
24%
Retinal Thickness
12%
Retinal Vein
12%
Retinal Vein Occlusion
49%
Short-term Outcomes
49%
Statistical Analysis
8%
Student's T-test
8%
Surgical Outcomes
49%
Tissue Plasminogen Activator (t-PA)
49%
Treatment Duration
10%
Type 1 Macular Neovascularization
24%
Visual Acuity
98%
Vitreoretinal Surgery
21%
Medicine and Dentistry
Age Related Macular Degeneration
24%
Best Corrected Visual Acuity
49%
Biofeedback
49%
Biosimilar
24%
Bleeding
24%
Central Retinal Vein Occlusion
49%
Endovascular Surgery
49%
Fluorescein Angiography
12%
Induced Pluripotent Stem Cell
9%
Intraocular Drug Administration
6%
Intravitreal Administration
6%
Laser Coagulation
6%
Macular Edema
12%
Macular Hole
98%
Neovascular Glaucoma
6%
Pars Plana Vitrectomy
5%
Postoperative Complication
6%
Recurrent Disease
6%
Retina Tear
24%
Retinal Surgery
24%
Retrospective Study
7%
Student T Test
8%
Subtenon Drug Administration
6%
Surgery
6%
Tissue Plasminogen Activator
52%
Transactivator Protein
9%
Triamcinolone Acetonide
6%
Vasculotropin
11%
Visual Acuity
100%
Vitreous
21%
Vitreous Hemorrhage
6%